Please login to the form below

Not currently logged in
Email:
Password:

adalimumab-atto

This page shows the latest adalimumab-atto news and features for those working in and with pharma, biotech and healthcare.

New EU and US approvals for Humira biosimilars

New EU and US approvals for Humira biosimilars

Humira (adalimumab) has been the wold's biggest selling drug for years, and made $16bn in sales last year for AbbVie, with a little under $6bn of that total coming from ... It is the second to claim marketing approval in the US market after Amgen's

Latest news

  • Amgen wins European approval for Humira biosimilar Amgevita Amgen wins European approval for Humira biosimilar Amgevita

    Amgevita (biosimilar adalimumab) is both Amgen’s first biosimilar and now the first Humira biosimilar to be approved in Europe. ... Amgen’s Humira biosimilar was approved last September in the US under the brand name Amjevita (adalimumab-atto), whose

  • Amgen claims first US go-ahead for Humira biosimilar Amgen claims first US go-ahead for Humira biosimilar

    brand. The approval is however just the first step in what is likely to be a long journey before the biosimilar - called Amjevita (adalimumab-atto; formerly ABP 501) - can be prescribed ... Meanwhile AbbVie has already filed a lawsuit against Amgen

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics